Section 4.5 (Interaction with other medicinal products and other forms of interaction) updated as follows:

Concurrent administration of lorazepam with sodium valproate may result in reduced clearance (20 to 40%) and increased concentrations of lorazepam.  Therefore clinical monitoring is advised and lorazepam dosage should be reduced when appropriate.

Concurrent administration of lorazepam with probenecid may result in reduced clearance, increased elimination half-life and increased concentrations of lorazepam.  Therefore clinical monitoring is advised and lorazepam dosage should be reduced when appropriate.